An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19
By
C. Garrett Rappazzo,
Longping V. Tse,
Chengzi I. Kaku,
Daniel Wrapp,
Mrunal Sakharkar,
Deli Huang,
Laura M. Deveau,
Thomas J. Yockachonis,
Andrew S Herbert,
Michael B. Battles,
Cecilia M. O'Brien,
Michael E. Brown,
James C. Geoghegan,
Jonathan Belk,
Linghang Peng,
Linlin Yang,
Trevor D. Scobey,
Dennis R. Burton,
David Nemazee,
John M Dye,
James E. Voss,
Bronwyn M Gunn,
Jason S McLellan,
Ralph Baric,
Lisa E. Gralinski,
Laura M Walker
Posted 17 Nov 2020
bioRxiv DOI: 10.1101/2020.11.17.385500
The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population underscores the need for broadly active countermeasures. Here, we employed a directed evolution approach to engineer three SARS-CoV-2 antibodies for enhanced neutralization breadth and potency. One of the affinity-matured variants, ADG-2, displays strong binding activity to a large panel of sarbecovirus receptor binding domains (RBDs) and neutralizes representative epidemic sarbecoviruses with remarkable potency. Structural and biochemical studies demonstrate that ADG-2 employs a unique angle of approach to recognize a highly conserved epitope overlapping the receptor binding site. In murine models of SARS-CoV and SARS-CoV-2 infection, passive transfer of ADG-2 provided complete protection against respiratory burden, viral replication in the lungs, and lung pathology. Altogether, ADG-2 represents a promising broad-spectrum therapeutic candidate for the treatment and prevention of SARS-CoV-2 and future emerging SARS-like CoVs. ### Competing Interest Statement C.G.R, C.I.K, M.S., L.M.D., M.B.B., M.E.B., J.C.G., and L.M.W. are employees of Adimab, LLC and may hold shares in Adimab, LLC. L.M.W. is an employee of Adagio Therapeutics Inc. and holds shares in Adagio Therapeutics Inc. D.R.B. is on the SAB of Adimab, LLC and Adagio Therapeutics Inc. and holds shares in Adimab, LLC.
Download data
- Downloaded 1,256 times
- Download rankings, all-time:
- Site-wide: 13,911
- In immunology: 386
- Year to date:
- Site-wide: 2,189
- Since beginning of last month:
- Site-wide: 2,189
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!